Table 3 Comparison of abnormal values of diagnostic markers between neoplasia and JIA patients
Diagnostic markers | All patients n/N (%) | Neoplasia n/N (%) | JIA n/N (%) | p-value (Neoplasia versus JIA) | Sensitivity | Specificity | PPV | NPV | LR+ | LR- |
|---|---|---|---|---|---|---|---|---|---|---|
WBC count | 66/128 (51.6) | 33/60 (55.0) | 33/68 (48.5) | 0.484 | ||||||
Neutrophil count | 27/116 (23.3) | 25/55 (45.5) | 2/61 (3.3) | 0.000 | 45.5% | 96.7% | 92.5% | 66.2% | 13.8 | 0.6 |
Platelet count | 98/128 (76.6) | 47/60 (78.3) | 51/68 (75.0) | 0.682 | ||||||
Hb | 40/128 (31.3) | 34/60 (56.7) | 6/68 (8.8) | 0.000 | 56.7% | 91.2% | 85.0% | 70.4% | 6.4 | 0.5 |
LDH | 84/107 (78.5) | 51/58 (87.9) | 33/49 (67.3) | 0.017 | 87.9% | 32.7% | 60.7% | 69.5% | 1.3 | 0.4 |
ESR | 87/105 (82.9) | 33/37 (89.2) | 54/68 (79.4) | 0.281 | ||||||
CRP | 86/113 (76.1) | 39/52 (75.0) | 47/61 (77.0) | 0.828 | ||||||
ANA | 35/81 (43.2) | 3/19 (15.8) | 32/62 (51.6) | 0.008 | 15.8% | 48.4% | 8.5% | 65.2% | 0.3 | 1.7 |
IgG | 38/108 (35.2) | 16/51 (31.4) | 22/57 (38.6) | 0.545 | ||||||
IgM | 8/108 (7.4) | 4/51 (7.8) | 4/57 (7.0) | 1.000 | ||||||
IgA | 26/108 (24.1) | 18/51 (35.3) | 8/57 (14.0) | 0.013 | 35.3% | 86.0% | 69.2% | 59.7% | 2.5 | 0.8 |
C3 | 47/90 (52.2) | 22/36 (61.1) | 25/54 (46.3) | 0.200 | ||||||
C4 | 26/89 (29.2) | 17/36 (47.2) | 9/53 (17.0) | 0.004 | 47.2% | 83.0% | 65.3% | 69.8% | 2.8 | 0.6 |
Anti-EBV IgM | 8/58 (13.8) | 7/44 (15.9) | 1/14 (7.1) | 0.665 | ||||||
Anti-EBV IgG | 41/59 (69.5) | 33/44 (75.0) | 8/15 (53.3) | 0.192 | ||||||
Anti-EA EBV IgG | 14/45 (31.1) | 14/35 (40.0) | 0/10 (0) | 0.019 | 40.0% | 100% | 1.0% | 32.2% | - | 0.6 |
Anti-CMV IgM | 4/44 (9.1) | 2/34 (5.9) | 2/10 (20.0) | 0.218 | ||||||
Anti-CMV IgG | 26.43 (60.5) | 24/33 (72.7) | 2/10 (20.0) | 0.007 | 72.7% | 80.0% | 92.3% | 47.0% | 3.6 | 0.3 |